ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?-Reference-Cited by-同舟云学术

ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?

Published:2022-02-02 Issue:4 Volume:22 Page:445-447
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Davis James A.¹^ORCID,Hashmi Hamza²

Affiliation:

1. MUSC College of Pharmacy, Malignant Hematology, Medical University of South Carolina, MUSC Hollings Cancer Center, Charleston29425

2. Hematology/Oncology, Division of Malignant Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston

Funder

no funding to report

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2022.2035357

Reference10 articles.

1. Molecular Mechanisms of Amyloidosis

2. Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis

3. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

4. Comenzo R. Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from andromeda. ASH; 2020 [cited 2021 Nov 21]. Available from https://ash.confex.com/ash/2020/webprogram/Paper137582.html

5. Sanchorawala V. Health-related quality of life in patients with AL amyloidosis treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone: results from the Phase 3 andromeda study. ASH; 2020 [cited 2021 Nov 21]. Available from: https://ash.confex.com/ash/2020/webprogram/Paper139438.html